Clinical Potential of Multimodal Therapeutics

This Event has Passed

Where

Virtual

When

{{getUserDateTimezone("1732291200").singleDate}}
{{getUserDateTimezone("1732291200").time}} - {{getUserDateTimezone("1732293000").time}} {{getClientTimezoneName()}}

About

As the clinical pipeline expands, researchers are testing mechanisms from across the drug landscape in combination to deliver innovative treatments.

Join us to explore how the biopharmaceutical industry is taking an outcome-based approach to developing unique multimodal therapeutics that push the boundaries of what we once thought was clinically possible.

Moderator

Jesse McQuarters, Branded Content Editor at STAT

Speakers

Palani Palaniappan, Chief Technology Officer, Pioneering Medicines

Leads the strategy & implementation of chemistry, manufacturing & controls (CMC) aspects of asset development, ensuring Pioneering Medicines establishes a world-class & cutting-edge technical operations function. He partners with ext. contract development, manufacturing orgs, and bioplatform companies to lead CMC/pharm. dev./manufacturing efforts for all PM’s programs.

Michael Chambers, Co-Founder and Chairman, Aldevron

Michael Chambers co-founded Aldevron in 1998. Aldevron evolved from a small NDSU lab into a cornerstone of the global genetic medicine industry. Today, Aldevron manufactures nucleic acids, recombinant enzymes, and products used in molecular diagnostics, cell and gene therapies, gene editing, and vaccines.

Daria Donati, Chief Scientific Officer, Genomic Medicine, Cytiva

Daria Donati has over 20 years of diverse management and technology solutions experience within biotech and biomanufacturing. Daria is the eyes and ears for Cytiva when it comes to finding new ways to grow and solve the most urgent challenges in the life sciences. She ensures that key scientific and technology inputs are integrated in all strategy, product development, and R&D processes.

Iwan Roberts, EngD, VP, Technology and Innovation Strategy, Cytiva

Iwan Roberts applies engineering principles to the industrial scale-up of both protein and cell-based therapies. In 2017 he sold his own start-up to GE Healthcare (which later became Cytiva). Across R&D, business development, and strategy, Iwan focuses on ensuring that health care innovators have access to the best solutions to enable them to bring transformative therapies to patients.